Intentional iron overdose in pregnancy--management and outcome.
The objectives of our study were to 1) determine if peak maternal serum iron level or toxicity stage after intentional overdose is associated with adverse maternal-fetal outcome, and 2) describe the use of deferoxamine antidote therapy in obstetric patients. A computer search of the English language literature from 1966-1998 used the key words iron toxicity, iron poisoning, deferoxamine, and pregnancy to identify peer-reviewed papers reporting intentional iron overdoses in pregnancy. Two investigators independently extracted data from articles and their references including stage of toxicity (0 = asymptomatic, 1 = gastrointestinal symptoms, 2 = metabolic disturbance, 3 = organ failure), with differences resolved by consensus. Statistical analysis used the Student t-test, Fisher exact test, or ANOVA, as appropriate. Fourteen publications were identified, describing 61 cases of obstetric iron overdose, including one recent case at our institution. Compared with women who had lower peak levels, women with peak serum iron levels > or =400 mcg/dL were more frequently symptomatic (12/13 vs. 5/10, respectively, p = 0.05). Peak iron level > or =400 mcg/dL was not associated with increased risk of spontaneous abortion, preterm delivery, congenital anomalies, or maternal death. However, patients with stage 3 toxicity were more likely to spontaneously abort (1/3 vs. 1/56, respectively), deliver preterm (2/3 vs. 6/56, respectively), or experience maternal death (3/3 vs. 0/56, respectively). The proportions of patients treated with deferoxamine and total dosages of deferoxamine were similar by peak iron level (> or =400 vs. <400 mcg/dL) and toxicity stage (0-3). Peak iron levels > or =400 mcg/dL are associated with symptomatic iron overdose. Stage 3 toxicity is associated with spontaneous abortion, preterm delivery, and maternal death.
Tran
T
T
Department of Obstetrics and Gynecology, Hartford Hospital, Connecticut 06102, USA.
Wax
J R
JR
Philput
C
C
Steinfeld
J D
JD
Ingardia
C J
CJ
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D002614:Chelating Agents / Q000008:administration & dosage; D003676:Deferoxamine / Q000627:therapeutic use; D062787:Drug Overdose / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D004636:Emergency Service, Hospital; D005260:Female; D005313:Fetal Death; D006801:Humans; D007501:Iron / Q000097:blood*; D058085:Iron Compounds / Q000506:poisoning*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood* / Q000139:chemically induced* / Q000188:drug therapy / Q000401:mortality; D011256:Pregnancy Outcome; D011336:Probability; D013406:Suicide, Attempted; D015996:Survival Rate
D002614:Chelating Agents; D058085:Iron Compounds; D007501:Iron; D003676:Deferoxamine